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Abstract. We present a 3D fully-automatic method for the calibration
of partial differential equation (PDE) models of glioblastoma (GBM)
growth with “mass effect”, the deformation of brain tissue due to the tu-
mor. We quantify the mass effect, tumor proliferation, tumor migration,
and the localized tumor initial condition from a single multiparame-
teric Magnetic Resonance Imaging (mpMRI) patient scan. The PDE is
a reaction-advection-diffusion partial differential equation coupled with
linear elasticity equations to capture mass effect. The single-scan cali-
bration model is notoriously difficult because the precancerous (healthy)
brain anatomy is unknown. To solve this inherently ill-posed and ill-
conditioned optimization problem, we introduce a novel inversion scheme
that uses multiple brain atlases as proxies for the healthy precancer pa-
tient brain resulting in robust and reliable parameter estimation. We
apply our method on both synthetic and clinical datasets representative
of the heterogeneous spatial landscape typically observed in glioblas-
tomas to demonstrate the validity and performance of our methods. In
the synthetic data, we report calibration errors (due to the ill-posedness
and our solution scheme) in the 10%-20% range. In the clinical data, we
report good quantitative agreement with the observed tumor and quali-
tative agreement with the mass effect (for which we do not have a ground
truth). Our method uses a minimal set of parameters and provides both
global and local quantitative measures of tumor infiltration and mass
effect.
Keywords: Glioblastoma ·Mass effect · Tumor growth models · Inverse
problems.
1 Introduction
Gliomas are the most common primary brain tumors in adults. Glioblastomas are
high grade gliomas with poor prognosis. A significant challenge in the character-
ization of these tumors involves mass effect (the deformation of the surrounding
healthy tissue due to tumor growth) along with biomarkers representing the
tumor aggressiveness and growth dynamics. The integration of mathematical
models with clinical imaging data holds the enormous promise of robust, mini-
mal, and explainable models that quantify cancer growth and connect cell-scale
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phenomena to organ-scale, personalized, clinical observables [17,25,23]. Here, we
focus on the calibration of mathematical tumor growth models with clinical
imaging data from a single pretreatment scan in order to assist in diagnosis and
treatment planning. Longitudinal pretreatment scans are rare for GBMs since
most patients seek immediate treatment. For this reason, we need algorithms
that rely only on one mpMRI scan.
Contributions: The single-scan calibration problem is formidable for two main
reasons: the tumor initial condition (IC) and the subject’s healthy precancer
anatomy are unknown. Using brain anatomy symmetry does not apply to all
subjects so typically an atlas is used as a proxy to the healthy subject brain.
However, natural anatomical differences between the atlas and the subject in-
terfere with tumor-related deformations; disentangling the two is hard. In light
of these difficulties, our contributions are as follows: • Based on the method
described in [21], we propose a novel multistage scheme for inversion: first we
estimate the tumor initial conditions, then, given an atlas, we invert for the three
scalar model parameters (proliferation, migration, mass effect). We repeat this
step for several atlases and we compute expectations of the observables (see §2
and §2.1). These calculations are quite expensive. However, the entire method
runs in parallel on GPUs so that 3D inversion in 1283 resolution takes less than
an hour and 2563 resolution takes about six hours. • We use synthetic data (for
which we know the ground truth) in order to estimate the errors associated with
our numerical scheme and we validate our method on a set of clinical mpMRI
scans. We report these results in §3.
Related work: The most common mathematical models for tumor growth
dynamics are based on reaction-diffusion PDEs [16,22,13,15,24], which have
been coupled with mechanical models to capture mass effect [10,3,11,20]. While
there have been many studies to calibrate these models using inverse prob-
lems [13,4,9,5,12,15,8,18], most do not invert for all unknown parameters (tumor
initial condition and model parameters) or they assume the presence of multiple
imaging scans (both these scenarios make the inverse problem more tractable).
In [21], the authors presented a methodology to invert for tumor initial con-
dition (IC) and cell proliferation and migration from a single scan; but their
forward (growth) model does not account for mass effect. They demonstrate the
importance of using a sparse tumor IC (see §2) to correctly reconstruct for other
tumor parameters. In [6], the author considers mathematical aspects of inverting
simultaneously for the tumor IC, tumor parameters, and mass effect but assumes
known precancer brain anatomy. Other than those works, the current state of
the art for single-scan biophysically-based tumor characterization is GLISTR [8].
The main shortcoming of GLISTR is that it requires manual seeding for the
tumor IC and uses a single atlas. Further, GLISTR uses deformable registration
for both anatomical variations and mass effect deformations but does not de-
couple them (this is extremely ill-posed), since the primary goal of GLISTR lies
in image segmentation. Finally, the authors in [1] present a 2D synthetic study
to quantify mass effect. However, they assume known tumor IC and precancer
brain. To the best of our knowledge, we are not aware of any other framework
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that can fully-automatically calibrate tumor growth models with mass effect for
all unknown parameters in 3D. Furthermore, our solvers employ efficient parallel
algorithms and GPU acceleration.
2 Methods
Before we describe our methods, we introduce the following notations: c = c(x, t)
is the tumor concentration (x is a voxel, t is time) with observed tumor data
c1 and unknown tumor IC c0; m(x, t) := (mWM(x, t),mGM(x, t),mCSF(x, t))
is the brain segmentation into white matter (WM), gray matter (GM), and
cerebrospinal fluid (CSF) with observed pretreatment segmented brain m1 and
unknown precancer healthy brain m0; Additionally, (κ, ρ, γ) are scalars that
represent the unknown migration rate, proliferation rate, and a mass effect pa-
rameter, respectively.
Tumor growth mathematical model: Following [20], we use a non-linear
reaction-advection-diffusion PDE (on an Eulerian framework):
∂tc+ div (cv)− κDc− ρRc = 0, c(0) = c0 in Ω × [0, 1] (1a)
∂tm+ div (m⊗ v) = 0, m(0) = m0 in Ω × [0, 1] (1b)
div (λ∇u+ µ(∇u+∇uT)) = γ∇c in Ω × [0, 1] (1c)
∂tu = v, u(0) = 0 in Ω × [0, 1], (1d)
where D := divmWM∇c is a diffusion operator; R := mWMc(1− c) is a logistic
growth operator; Eq. (1a) is coupled to a linear elasticity equation (Eq. (1c))
with forcing γ∇c, which is coupled back through a convective term with velocity
v(x, t) which parameterizes the displacement u(x, t). The linear elasticity model
is parameterized by Lame` coefficients λ(x, t) and µ(x, t). We note here that
γ = 0 implies u = 0, which reduces the tumor growth model to a simple reaction-
diffusion PDE with no mass effect (i.e, Eq. (1a) with v = 0).
Following [21], we parameterize c0 = φ
T (x)p =
∑m
i=1 φi(x)pi; where p is
an m-dimensional parameterization vector, φi(x) = φi(x− xi, σ) is a Gaussian
function centered at point xi with standard deviation σ, and φ(x) = {φi(x)}mi=1.
Here, xi are voxels that are segmented as tumor and σ is one voxel, meaning
m can be quite large (∼1000). This parameterization alleviates some of the ill-
posedness associated with the inverse problem [21].
Inverse problem: The unknowns in our growth model are (p,m0, κ, ρ, γ). Our
model is calibrated for these parameters using imaging data. We introduce an
approximation to m0 (discussed in the numerical scheme), and estimate the rest
through the following inverse problem formulation:
min
p,κ,ρ,γ
J (p, κ, ρ, γ) := 1
2
‖Oc(1)− c1‖2L2(Ω) +
β
2
‖φTp‖2L2(Ω) (2)
subject to the reaction-advection-diffusion forward (growth) model F(p, κ, ρ, γ)
given by Eq. (1). Recall that κ, ρ, and γ are scalars, but p ∈ Rm. The objective
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function minimizes the L2 mismatch between the simulated tumor c(1) at t = 1
and data c1 and is balanced by a regularization term on the inverted initial
condition (IC). O is an observation operator that defines the clearly observable
tumor margin (see [19] for details). Following [21], we further introduce the
following constraints to our optimization problem: ‖p‖0 ≤ s and max(φTp) = 1.
The first constraint restricts the tumor initial condition to a few Gaussians while
the second enforces the assumption that t = 0 corresponds to the first time the
tumor concentration reaches one at some voxel in the domain. Note that these
two constraints are modeling assumptions. They are introduced to alleviate the
severe ill-posedness of the backward tumor growth PDE (see [21] for details).
2.1 Summary of our multistage inversion method
To solve our inverse problem, we propose the following numerical scheme:
(S.1) We solve Eq. (2) using the simple growth model with no mass effect
F(p, κ, ρ, γ = 0)1 for (p, κ, ρ). In this step, our precancer scan, i.e. m0, is
approximated as the patient brain with tumor regions replaced by white
matter. In order to solve the resulting non-linear inverse problem, we em-
ploy the fast adjoint-based algorithm outlined in [21].
(S.2) Next, due to mass effect, we need an estimate for m0. For this, we use
m0(x) = a(x), where a(x) is an atlas or a scan from another healthy
individual. We note that the inverted tumor initial condition prec lies in
the precancer scan space from (S.1). In order to make sure that the prec
locations do not fall in anatomical structures such as ventricles (where the
tumor does not grow), we register the patient2 and the atlas (our new
precancer scan), and transfer (warp) the initial condition to the atlas with
the deformation map. This registration is unnecessary if the precancer
scan is known.
(S.3) Finally, we solve Eq. (2) constrained by F(p = prec, κ, ρ, γ) for (κ, ρ, γ).
Since we have only three unknown parameters, we use first order finite
differences to approximate the gradient of the objective.
We repeat (S.2) and (S.3) for different atlases to make our inversion scheme
less sensitive to the atlas selected. For the `2 regularized solve in (S.1) and the
inverse solve in (S.3), we use a quasi-Newton optimization method (L-BFGS)
globalized by Armijo linesearch with gradient-based convergence criteria. For
the registration in (S.2), we use the registration solver CLAIRE [14].
Solver timings: On average, the full multistage inversion on 1283 takes less than
an hour using GPUs. The inversion in the different atlases are embarrassingly
parallel. For 2563 (the resolution of our results), the full inversion takes an av-
erage of six hours. Finally, our optimization solvers converge in an average of
20-30 quasi-Newton iterations without any failures.
1 γ = 0 indicates no mass effect and Eq. (1b), Eq. (1c) and Eq. (1d) are not needed.
2 We simply mask the tumor region of the patient for this registration.
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3 Results
We ask the following four questions:
(Q1) Given p (tumor IC) and m0 (precancer scan), can we reconstruct (κ, ρ, γ)
using (S.3) from §2.1?
(Q2) Given m0 but unknown p, can we reconstruct (p, κ, ρ, γ) using (S.1) and
(S.3)?
(Q3) With m0 and p unknown, can we reconstruct (p, κ, ρ, γ) using (S.1)-(S.3)
taking different atlases as m0?
(Q4) How does our scheme perform on clinical data?
We use synthetic data to answer (i)-(iii) and quantify our errors. For clinical
data, since the ground truth is unknown (we do not have longitudinal data), we
evaluate our scheme qualitatively.
(Q1) Known m0, known p: In this experiment, we generate data by growing
synthetic tumors resembling clinical observations in a healthy atlas using differ-
ent ground truth parameter combinations. The test-cases are aimed at simulating
similar tumor volumes, but with varying amount of mass effect. We consider the
following variations for our parameter configurations:
(i) TC(a): no mass effect γ? = 0 ρ? = 12 κ? = 0.025
(ii) TC(b): mild mass effect γ? = 0.4 ρ? = 12 κ? = 0.025
(iii) TC(c): moderate mass effect γ? = 0.8 ρ? = 10 κ? = 0.05
(iv) TC(d): large mass effect γ? = 1.2 ρ? = 10 κ? = 0.025,
where ? represents the non-dimensionalized ground truth parameters. The tu-
mors along with the deformed atlas are visualized in Fig. 1. We report our in-
version results in Tab. 1 (“True IC”) with tumor initial condition and precancer
scan taken as the ground truth. We report the relative errors in reconstructing
parameters ι = {κ, ρ, γ} (if the ground truth is zero, then the error is absolute;
TC(a)), relative error in the two-norm of the displacement norm u, i.e., ‖u‖2
(this field informs us of the extent of mass effect), relative error in the final
tumor reconstruction, and the norm of the gradient to indicate convergence. We
observe excellent reconstruction with relative errors less than 2%.
(Q2) Known m0, unknown p: We use our inversion scheme outlined in §2.1,
where we first invert for the tumor initial condition using (S.1) and then the
model parameters with known precancer scan. We report our inversion results
in Tab. 1 under “Inverted IC”. As expected, the errors increase due to the fact
that we reconstructed p (IC) using the no-mass-effect model (images of the
reconstructions included in supplementary Fig. S1). But we can still recover the
model parameters quite well: the mass effect (indicated by the error in two-
norm of the displacement norm eu) is captured with relative errors less that 4%;
the reaction and diffusion coefficient also have good estimates of around 15%
and 22% average relative errors respectively. Hence, our scheme exhibits good
reconstruction performance.
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TC(a) TC(b) TC(c) TC(d)
0
1
Fig. 1: Synthetic patient T1 MRIs generated with Eq. (1). The normalized tu-
mor concentration is overlaid (color) along with the undeformed ventricles (black
dashed contour) to indicate the variable extent of mass effect.
Table 1: Inversion results assuming known m0, the anatomy of the subject
before tumor occurrence. u? is the ground truth displacement norm in number
of voxels (1 voxel ≈ 0.9 mm), eι is the relative error for parameter ι, eu is the
relative error in the two-norm of the displacement field norm, ‖g‖2 is the norm of
the final gradient, and µT,L2 is the relative error in final tumor concentration. We
report the tumor initial condition (IC) used in “Tumor IC” – True IC indicates
synthetic ground truth IC and Inverted IC indicates our reconstruction using
(S.1) and (S.3).
Test-case Tumor IC eγ eρ eκ ‖u?‖∞ eu ‖g‖2 µT,L2
TC (a) True IC 4.44E−6 2.26E−3 2.76E−3 0 4.63E−4 1.54E−1 3.28E−3
TC (b) True IC 1.50E−3 2.69E−3 1.39E−2 6.1 7.27E−4 5.70E−4 3.52E−3
TC (c) True IC 1.32E−3 2.50E−5 2.14E−4 10 1.49E−3 4.81E−5 7.18E−4
TC (d) True IC 2.17E−4 1.00E−5 3.12E−4 14.9 4.61E−4 6.26E−5 3.35E−4
TC (a) Inverted IC 2.95E−3 1.63E−1 2.08E−1 0 2.86E−1 1.27E−2 2.42E−1
TC (b) Inverted IC 5.29E−2 1.29E−1 1.94E−1 6.1 4.93E−3 6.43E−4 2.12E−1
TC (c) Inverted IC 3.54E−2 1.39E−1 2.55E−1 10 1.46E−2 3.54E−4 1.65E−1
TC (d) Inverted IC 1.46E−2 1.59E−1 2.16E−1 14.9 3.78E−2 7.48E−4 1.88E−1
(Q3) Unknown m0, unknown p: This scenario corresponds to the actual
clinical problem. For this test-case, we invoke (S.2) and average the results using
three atlases. To reiterate the scheme, the inverted tumor ICs from (S.1) are
warped to each atlas (through registration) for the final inversion (S.3). We
report inversion results in Tab. 2 and show an exemplary reconstruction of the
patient using the different atlases in Fig. 2. Despite the approximation error in
m0, we are still able to capture the parameters (average displacement relative
errors of around 16% and 25% for atlases (1) and (2) respectively). Atlas (3)
has poor performance because it is significantly different from the patient (for
example, the ventricles are highly dissimilar). We also note that the error in
tumor reconstruction is significantly higher, which is representative of the errors
introduced due to the anatomical variations of each atlas from the patient.
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Table 2: Inversion results for unknown m0 and p. eι are the relative errors
in parameter ι. Atlas (*) are the different atlases used. True atlas is the ground
truth m0. u
? is the ground truth displacement norm in number of voxels, ‖g‖2 is
the norm of the final gradient, and µT,L2 is the relative error in the final tumor
concentration .
ID Test-case eγ eρ eκ ‖u?‖∞ eu ‖g‖2 µT,L2
TC (d)
True atlas 2.48E−2 1.81E−1 2.54E−1 14.9 2.91E−2 5.75E−4 2.05E−1
Atlas (1) 1.63E−2 2.15E−1 2.65E−1 14.9 1.21E−1 2.71E−4 3.37E−1
Atlas (2) 1.13E−1 2.35E−1 9.27E−2 14.9 2.00E−1 6.85E−4 3.04E−1
Atlas (3) 2.50E−1 2.06E−1 5.46E−1 14.9 2.39E−1 5.43E−4 2.79E−1
True atlas Atlas (1) Atlas (2) Atlas (3)
0
1
Fig. 2: Reconstruction of the tumor concentration (color) using different atlases
as the precancer scan. The tumor data segmentation is highlighted as a black
dashed contour line.
(Q4) Clinical images: We use images from the BraTS [2] dataset. We segment
the scans using a neural network based on [7] and use the segmented tumor core
as tumor data. We select four patients with visually different but, of course,
unknown mass effect. For each patient, we invert in four different atlases used
as m0. For each BraTS case, we report atlas-averaged model parameters. We
show each patient with the average reconstructed tumor and displacement norm
in Fig. 3. We quantify mass effect using the average maximum displacement
norm, ‖u‖∞. We observe that ABO and AAP show high mass effect (‖u‖∞ ∼
18 mm ± 1). For ALU, the mass effect is moderate (‖u‖∞ ∼ 8 mm ± 2) and is
localized at the side of the brain around the tumor (see Fig. 3); the ventricles
are largely undeformed. Finally, AMH has a mild to moderate predicted mass
effect (‖u‖∞ ∼ 5 mm± 3) but exhibits the largest variation.
4 Conclusions
Our results are very promising. First, our solver is robust (never crashes, takes
excessive iterations, or needs subject-specific hyperparameter settings). Most im-
portant, our method does not require any manual preprocessing and can be run
in a black box fashion. Our experiments on synthetic data with known ground
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ABO (cpred) ABO (upred) AMH (cpred) AMH (upred)
AAP (cpred) AAP (upred) ALU (cpred) ALU (upred)
Fig. 3: Predicted normalized tumor (cpred) and mass effect displacement norm
(upred) for each BraTS subject. The tumor data segmentation is also overlaid:
the tumor core segmentation is outlined with the white dashed contour and the
edema segmentation with the black dashed contour. Higher tumor concentrations
(∼ 1) are indicated by red and lower ones by green. Higher displacement norm
values (∼ 18 mm) are indicated by red and lower ones by green.
truth is the first time that such a solver is verified (for example, no such verifica-
tion is undertaken in GLISTR) and we demonstrated that our approximations do
not introduce significant errors despite the fact that m0 is unknown. For clinical
data, the model errors are expected to dominate the errors from using an atlas
and splitting the calibration procedure into two stages. Second, we tested our
method on a small number of clinical scans in order to test the feasibility of our
method. With a very small number of calibration parameters, our solver was able
to quantitatively match the observed tumor margins and qualitatively correlate
with observed mass effect. We observed significant variability across subjects
and small variability with respect to the choice of atlas. Our method provides a
means to quantify and localize the mass effect without relying on any assump-
tions on symmetry and location of the tumor. It also provides quantitative mass
effect measures for comparing and stratifying subjects. The biophysical features
can complement other radiogenomic features in downstream learning tasks. Our
next step is further validation using a much larger clinical dataset and the use
of a large number of atlases.
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Supplementary materials
Table S1: Model and inversion parameter values used in our simulations. Note
that the Lame` coefficients λ and µ are determined by the Young’s modulus and
Poisson’s ratio of the tissue-type.
Parameter value
Spatial discretization 2563
Young’s modulus of (GM, WM, CSF, tumor) (Pa) (2100, 2100, 100, 8000)
Poisson’s ratio of (GM, WM, CSF, tumor) (0.4, 0.4, 0.1, 0.45)
Gaussian width, σ (voxels) 1
Regularization parameter, β 1E-4
Relative gradient tolerance 1E-3
Relative objective function change tolerance 1E-3
Maximum number of quasi-Newton iterations 50
Fig. S1: Estimated tumor initial conditions p reconstructed using the algorithm
in (S.1) for test-case TC(d). The size of the markers indicate the magnitude of
activation. The blue marker is the ground truth; the red markers represent the
reconstruction. The tumor concentration is overlaid (red: high concentration,
green: low concentration). Due to ill-posedness, the exact reconstructions cannot
be recovered.
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Table S2: Inversion results for unknown precancer scan and tumor IC. u?
is the ground truth displacement norm in number of voxels, eι is the relative error
for parameter ι, eu is the relative error in the two-norm of the displacement field
norm, ‖g‖2 is the norm of the final gradient, and µT,L2 is the relative error in
tumor concentration at t = 1. Atlas (*) are different atlases used to approximate
the precancer scan; True atlas is the ground truth precancer scan.
ID Test-case eγ eρ eκ ‖u?‖∞ eu ‖g‖2 µT,L2
TC (a)
True atlas 6.50E−3 1.88E−1 2.68E−1 0 6.27E−1 2.04E−4 2.95E−1
Atlas (1) 1.30E−1 2.85E−1 3.32E−1 0 1.12E1 5.21E−4 4.76E−1
Atlas (2) 5.86E−2 2.66E−1 3.02E−1 0 5.39E0 1.92E−3 4.36E−1
Atlas (3) 1.88E−1 2.74E−1 3.44E−1 0 1.69E1 2.13E−3 4.84E−1
TC (b)
True atlas 3.49E−2 1.35E−1 3.38E−1 6.1 1.47E−2 5.69E−4 2.23E−1
Atlas (1) 1.40E−1 2.37E−1 1.20E−2 6.1 2.40E−1 7.00E−4 3.85E−1
Atlas (2) 1.86E−1 2.25E−1 1.86E−1 6.1 2.66E−1 1.44E−3 3.42E−1
Atlas (3) 1.07E0 2.02E−1 5.54E−1 6.1 8.76E−1 4.33E−4 3.99E−1
TC (c)
True atlas 1.03E−2 1.80E−1 2.47E−1 10 6.28E−2 3.66E−4 1.78E−1
Atlas (1) 5.84E−3 2.21E−1 3.48E−1 10 1.06E−1 9.18E−5 3.18E−1
Atlas (2) 2.08E−1 2.17E−1 2.01E−1 10 2.75E−1 1.50E−4 2.87E−1
Atlas (3) 6.08E−1 1.81E−1 5.63E−1 10 4.90E−1 7.11E−4 3.56E−1
TC (d)
True atlas 2.48E−2 1.81E−1 2.54E−1 14.9 2.91E−2 5.75E−4 2.05E−1
Atlas (1) 1.63E−2 2.15E−1 2.65E−1 14.9 1.21E−1 2.71E−4 3.37E−1
Atlas (2) 1.13E−1 2.35E−1 9.27E−2 14.9 2.00E−1 6.85E−4 3.04E−1
Atlas (3) 2.50E−1 2.06E−1 5.46E−1 14.9 2.39E−1 5.43E−4 2.79E−1
Table S3: Inversion results for clinical images using statistics from four at-
lases. We report average parameter values for (γ, ρ, κ, ‖u‖∞) along with the av-
erage relative error in tumor reconstruction (µT,L2) at observation points. We
also report the standard deviation for each metric.
Patient-ID γ ρ κ ‖u‖∞ (in voxels) µT,L2
ABO 8.78E−1 ± 3.97E−2 1.37E1 ± 6.45E−1 7.36E−3 ± 1.77E−3 20.9 ± 1.11 4.37E−1 ± 2.25E−2
AMH 4.44E−1 ± 3.33E−1 1.46E1 ± 5.31E−1 9.98E−3 ± 5.00E−3 5.55 ± 3.95 6.48E−1 ± 3.01E−2
AAP 1.40E0 ± 8.85E−2 1.37E1 ± 8.63E−1 5.00E−3 ± 1.33E−6 21.2 ± 0.94 5.76E−1 ± 1.27E−2
ALU 1.08E0 ± 2.37E−1 9.11E0 ± 1.81E−1 5.00E−3 ± 0.00E0 9.23 ± 2.08 4.42E−1 ± 4.36E−2
